Erectile Dysfunction Final
Erectile Dysfunction Final
Erectile dysfunction
Autonomic
Somatic
Autonomic Nerve supply
Parasympathetic – S2-S4 – primarily controls
erectile function
Sympathtic – T11-L2 – control detumescene and
also contribute to ejaculation and emission.
Somatic Nerve supply
Peripheral nerves(dorsal penile and pudendal
nerves) form sensory and motor element through a
reflex arc in the sacral spinal cord.
Sympathetic – norepinephrine –
vasoconstriction – detumescene (flaccid).
Phases of erection
Phases Term
0 Flaccid phase
2 Tumescent phase
5 Detumescence phase
Definition of Erectile dysfunction
or impotence
I.M.P.O.T.E.N.C.E mneumonic
Chordee disease(congenital penile
curvature)
Types of Erectile dysfunction
Primary ED ( ex: the man has never been able to attain or
sustain erections) is rare and is almost always due to psychologic
factors(guilt, fear of intimacy , depression, severe anxiety) or
clinically obvious anatomic abnormalities.
History
Examination
Investigation
History
Sexual
Some symptoms suggest psychogenic ED, and others
suggest organic disease
A psychogenic cause is suggested by the sudden onset of
ED or the presence of ED under some circumstances but
complete erection at other times.
In contrast, gradual deterioration of erectile quality over
months or years with preservation of libido suggests organic
disease.
Psychological evaluation.
History
Medical
Inquiries should be made about: DM, HTN, smoking,
hypercholesterolemia, and hyperlipidemia as well as about
liver, renal, vascular, neurologic, psychiatric, and endocrine
disease.
Surgical history
Abdominal, pelvic, perineal
Drug history
Androgenic substances are associated with decreased
serum testosterone levels and decreased libido.
physical examination
External Genitalia
Penis: phimosis, penile lesions
Testis: size, consistency
DRE
Investigation
LAB:
Recommended: Fasting glucose, lipid profile,
hormonal profile
Others: thyroid, PSA, prolactin
Principles of treatment
The primary goal in the management of strategy of a patient
with ED is to determine the etiology of the disease and treat it
when possible, and not to treat the symptom alone.
3. psychosexual counseling:
PDE5 inhibitors:
It is recommended as first line therapy
according to the AUA guidelines.
Treatment
Blocks the breakdown of cGMP, thus maintaining erection
(Chelsea et al 2006)
Management of non-responders
1. Patient education
2. Improved of related co morbid conditions
3. Normalizing testosterone level
4. Switching PDE5 inhibitors
5. Daily or continuous use of PDE5 inhibitors
6. Psychosocial counseling
7. Combined therapy
Medicated urethral system for
erection
Intra-urethral alprostadil
Introduced in 1990
Mechanism: activate adenylate cyclase
Erection starts 5-20min after administration
Contra-indication: 1.distal urethral stricture 2. significant
angulation or fibrosis 3. balantitis or urethritis 4. sexual
activity with pregnant female
Side effects: pain, bleeding, priapism and hypotension
Intra-cavernous injection
Introduced in 1990
Side effect: priapism, fibrosis , pain and hypotension
Vacuum constriction devices
Mechanically create negative pressure surrounding penis
Engorge penis with blood
Ring to prevent venous leakage
Penile prosthesis
The third line therapy after failure of other lines
Has the highest satisfaction rates (70-87%) among
treatment options for ED.
(EUA Guidelines 2009)
the 2 main complications of penile prosthesis
implantation are mechanical failure and infection.
Reference